Endurant Capital Management LP Fate Therapeutics Inc Transaction History

Endurant Capital Management LP

$0
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $211,724 - $504,780	11,908 Added 19.94%	71,640 $1.78 Million
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $664,815 - $1.35 Million	22,407 Added 60.03%	59,732 $2.32 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $1.79 Million - $2.4 Million	37,325 New	37,325 $2.18 Million
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $3.02 Million - $4.89 Million	-51,031 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $2.53 Million - $3.48 Million	37,599 Added 279.92%	51,031 $4.43 Million
Q1 2021 May 17, 2021	SELL	$72.16 - $117.4 $3.84 Million - $6.24 Million	-53,153 Reduced 79.83%	13,432 $1.11 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $395,183 - $1.05 Million	10,375 Added 18.46%	66,585 $6.06 Million
Q3 2020 Nov 16, 2020	SELL	$30.41 - $40.5 $142,379 - $189,621	-4,682 Reduced 7.69%	56,210 $2.25 Million
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $407,433 - $710,236	20,160 Added 49.49%	60,892 $2.09 Million
Q1 2020 May 15, 2020	SELL	$17.28 - $31.88 $1.63 Million - $3.01 Million	-94,290 Reduced 69.83%	40,732 $905,000
Q4 2019 Feb 14, 2020	SELL	$13.39 - $20.73 $425,266 - $658,384	-31,760 Reduced 19.04%	135,022 $2.64 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $2.58 Million - $3.75 Million	166,782 New	166,782 $2.59 Million
Q4 2018 Feb 14, 2019	SELL	$11.48 - $16.98 $2.35 Million - $3.47 Million	-204,333 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $1.07 Million - $1.98 Million	121,761 Added 147.46%	204,333 $3.33 Million
Q2 2018 Aug 14, 2018	SELL	$9.16 - $13.48 $666,591 - $980,966	-72,772 Reduced 46.85%	82,572 $936,000
Q1 2018 May 15, 2018	SELL	$6.3 - $13.77 $2.53 Million - $5.53 Million	-401,335 Reduced 72.09%	155,344 $1.52 Million
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $1.12 Million - $1.89 Million	283,979 Added 104.14%	556,679 $3.4 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $709,020 - $1.18 Million	272,700	272,700 $1.08 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

Redmile Group, LLC San Francisco, CA

13.2M
Shares

$21.9 Million
3.01% of portfolio
Vanguard Group Inc Valley Forge, PA

10.4M
Shares

$17.3 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$16.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

5.57M
Shares

$9.25 Million
0.72% of portfolio
State Street Corp Boston, MA

5.25M
Shares

$8.72 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Endurant Capital Management LP with notifications on news.

Account